Frontage Holdings Corp
HKEX:1521

Watchlist Manager
Frontage Holdings Corp Logo
Frontage Holdings Corp
HKEX:1521
Watchlist
Price: 1.67 HKD 0.6%
Market Cap: 3.4B HKD
Have any thoughts about
Frontage Holdings Corp?
Write Note

Frontage Holdings Corp
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Frontage Holdings Corp
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Frontage Holdings Corp
HKEX:1521
Income from Continuing Operations
$10.7m
CAGR 3-Years
-15%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Income from Continuing Operations
$6.2B
CAGR 3-Years
-10%
CAGR 5-Years
11%
CAGR 10-Years
14%
Danaher Corp
NYSE:DHR
Income from Continuing Operations
$3.6B
CAGR 3-Years
-15%
CAGR 5-Years
11%
CAGR 10-Years
3%
Mettler-Toledo International Inc
NYSE:MTD
Income from Continuing Operations
$795.6m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Income from Continuing Operations
$1.4B
CAGR 3-Years
13%
CAGR 5-Years
5%
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Income from Continuing Operations
$1.4B
CAGR 3-Years
22%
CAGR 5-Years
39%
CAGR 10-Years
16%
No Stocks Found

Frontage Holdings Corp
Glance View

Market Cap
3.4B HKD
Industry
Life Sciences Tools & Services

Frontage Holdings Corp. engages in the provision of research and analytical and development services throughout the drug discovery and development process. The company is headquartered in Exton, Pennsylvania. The company went IPO on 2019-05-30. Its segments include North America and the People’s Republic of China (PRC). Its North America segment, including laboratory testing, chemistry, manufacturing and control (CMC), preclinical research and chemistry services in the United States of America and Canada. Its PRC segment including laboratory testing, CMC, preclinical research, bioequivalence clinical and chemistry services in the PRC. Its preclinical research includes drug metabolism and pharmacokinetic (DMPK), safety, chemical and toxicology, and laboratory testing, including bioanalytical and biologics, and central laboratory. Its services and solutions include drug candidate evaluation, product development, clinical services and central laboratory and testing services.

Intrinsic Value
2.65 HKD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Frontage Holdings Corp's Income from Continuing Operations?
Income from Continuing Operations
10.7m USD

Based on the financial report for Dec 31, 2023, Frontage Holdings Corp's Income from Continuing Operations amounts to 10.7m USD.

What is Frontage Holdings Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-1%

Over the last year, the Income from Continuing Operations growth was -59%. The average annual Income from Continuing Operations growth rates for Frontage Holdings Corp have been -15% over the past three years , -1% over the past five years .

Back to Top